Metabolic effects of prenalterol in diabetic patients.
In 16 non-diabetic and 16 diabetic patients prenalterol, dobutamine and dopamine infusions (5 micrograms/kg/min for 30 min) were given. The haemodynamic and metabolic changes were similar in diabetics and non-diabetics. Prenalterol has the most pronounced haemodynamic effect on heart rate (increase 25-47%) and the heart rate-blood pressure-product (increase 54-81%). The metabolic effects were moderate. The slight lipolytic effect of prenalterol documented its functional selectivity for beta 1-adrenoceptors.
D000318:Adrenergic beta-Agonists / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002096:C-Peptide / Q000097:blood; D003920:Diabetes Mellitus / Q000378:metabolism*; D004280:Dobutamine / Q000008:administration & dosage / Q000494:pharmacology; D004298:Dopamine / Q000008:administration & dosage / Q000494:pharmacology; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007263:Infusions, Parenteral; D008066:Lipolysis / Q000187:drug effects*; D008875:Middle Aged; D011217:Practolol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000494:pharmacology; D011294:Prenalterol
D000318:Adrenergic beta-Agonists; D002096:C-Peptide; D004280:Dobutamine; D011294:Prenalterol; D011217:Practolol; D004298:Dopamine